Big Money Sentiment increased to 2.39 in 2018 Q4. It has change of 0.81, from 2018Q3’s 1.58. The ratio is positive due to AtriCure, Inc. positioning: 12 sold and 26 reduced. 39 funds bought stakes and 52 increased stakes. Investors holded 27.72 million in 2018Q3 but now own 31.33 million shares or 13.02% more.
Ameriprise Fincl Inc holds 0% or 165,382 shs in its capital. Regions Fincl holds 1,251 shs. Dafna Cap Mngmt Limited Liability Corporation holds 4.85% of its capital in AtriCure, Inc. (NASDAQ:ATRC) for 318,729 shs. D E Shaw And reported 0.01% stake. Credit Suisse Ag reported 28,265 shs stake. Macquarie Ltd holds 0% of its capital in AtriCure, Inc. (NASDAQ:ATRC) for 65,786 shs. Weiss Multi accumulated 0.01% or 10,000 shs. Cortina Asset Mgmt invested 0.56% in AtriCure, Inc. (NASDAQ:ATRC). Sectoral Asset Management has 355,728 shs. Suntrust Banks Inc has 0% invested in AtriCure, Inc. (NASDAQ:ATRC) for 12,500 shs. United Cap Finance Advisers Ltd holds 20,004 shs. Wasatch Advsr Incorporated holds 398,783 shs or 0.16% of its capital. Wellington Mgmt Group Ltd Liability Partnership owns 2.73 million shs. Legal & General Grp Pcl reported 6,958 shs. Pub Employees Retirement Sys Of Ohio owns 124,550 shs or 0.02% of their US capital.

On April, 25 is awaited AtriCure, Inc. (NASDAQ:ATRC)’s earnings report, RTT reports. Last year’s earnings per share was $-0.31, while now analysts expect change of 38.71 % up from current $-0.19 earnings per share. -9.52 % EPS growth is what Wall Street’s sees after $-0.21 reported EPS previous quarter. ATRC touched $26.79 during the last trading session after $0.41 change.AtriCure, Inc. has 220,199 shares volume, 1.19% up from normal. ATRC is uptrending and has moved 65.27% since March 30, 2018. ATRC outperformed by 60.90% the S&P500.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

A total of 2 analysts rate AtriCure (NASDAQ:ATRC) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ATRC) has 3 ratings reports on Mar 30, 2019 according to StockzIntelligence. In Friday, March 1 report Needham maintained it with “Buy” rating and $39 target. On Tuesday, October 9 the rating was maintained by Canaccord Genuity with “Buy”.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally.The company has $1.03 billion market cap. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.Last it reported negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

For more AtriCure, Inc. (NASDAQ:ATRC) news posted recently go to: Seekingalpha.com, Bizjournals.com, Streetinsider.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “AtriCure files for mixed shelf and sale of stock by current investors – Seeking Alpha” posted on March 01, 2019, “These were the best Cincinnati stocks in 2018 – Cincinnati Business Courier” on January 02, 2019, “AtriCure (ATRC) Reports Prelim. 3Q18 Revenues Above Consensus – StreetInsider.com” with a publish date: October 03, 2018, “Noteworthy Friday Option Activity: XENT, AFL, ATRC – Nasdaq” and the last “AtriCure misses by $0.04, beats on revenue – Seeking Alpha” with publication date: February 28, 2019.